Uthaamani Nei(Internal) and Nellikkai thylam (External) in the management of Mantha Sanni (Autism spectrum disorder)

Clinical Evaluation and Therapeutic Management of Mantha Sanni (Autism Spectrum disorder) by Uthaamani Nei( Internal) along with Nellikkai Thylam (External)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035524

Enrollment

Registered

2021-08-09

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: Uthaamani Nei (Internal) Nellikkai Thylam (External): Uthaamani Nei in the management of Autism spectrum disorder with the dosage of 3 to 5 years - 8 ml, 6 to 9 years - 10 ml, 10 to 12

Eligibility

Inclusion criteria

Inclusion criteria: Children of age group under 3-12 years Clinically diagnosed as Autism Spectrum Disorder (ASD) Meets the diagnostic symptoms of Has poor eye contact Inappropriate emotional response Acquired speech or lost it Engages in stereotyped and repetitive behaviour Unusual sensitive to sensory stimuli

Exclusion criteria

Exclusion criteria: -H/O Attention deficit hyperactivity disorder(ADHD) H/O Seizures and epilepsy H/O Cerebral palsy H/O Hearing and visual impairments H/O Congenital anomalies Any other serious illness

Design outcomes

Primary

Measure	Time frame
Efficacy of the trial drug assessed by INDIAN SCALE FOR ASSESEMENT OF AUTISM (ISAA) after 48days of treatment.Timepoint: 48 days	—

Secondary

Measure	Time frame
Improvement in the clinical symptoms.Timepoint: forty nineth day	—

Countries

India

Contacts

Public ContactDr Roshan M

National Institute of Siddha

drarulmozhi2012@gmail.com9500151930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026